Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mu…
| Periodo | 2026-08 | 2025-08 |
|---|---|---|
| Real | — | — |
| Estimado | — | — |
| Sorpresa | — | — |
| Métrica | AAPG | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 97.0% | 57.4% | +39.6% |
| Operating Margin | — | -34.4% | — |
| Net Margin | -41.3% | -32.5% | -8.9% |
| FCF Margin | -13.8% | -12.6% | -1.2% |
| ROE | -153.5% | -39.2% | -114.3% |
| ROA | — | -30.9% | — |
| Current Ratio | 1.26 | 2.73 | -1.47 |
| Debt / Equity | 3.37 | 0.28 | +3.09 |
| Tendencia (Piotroski) | FY24 | FY23 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | — | — |
| ✗Flujo de caja operativo positivo | −CN¥111M | −CN¥726M |
| –Rentabilidad sobre activos al alza | — | — |
| –Caja operativa/activos supera al ROA | — | — |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | 1.26 | 1.44 |
| ✗Sin aumentar el nº de acciones | 303M | 282M |
| ✓Margen bruto al alza | 97.0% | 86.2% |
| –Rotación de activos al alza | — | — |
| Calidad del negocio | FY24 |
|---|---|
| ✗Margen FCF > 10 % | -13.8% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 99.1% |
ASCENTAGE PHARMA GROUP INTERNATIONAL cotiza a 15.37 USD y tiene una capitalización bursátil de $1.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud